Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

MissionIRNewsBreaks — D-Wave Quantum Inc. (NYSE: QBTS) Schedules Q4, FY 2023 Earnings Call

D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, plans to release its financial results for the fourth quarter and fiscal year 2023 for the period ended Dec. 31, 2023 before market open on March 28, 2024.

In addition, the company has scheduled a conference call that same day to discuss the financial report along with the company outlook; the call is scheduled to begin at 8 a.m. ET. D-Wave CEO Dr. Alan Baratz and CFO John Markovich will host the call. Those wanting to access the call can dial 1-800-267-6316 (domestic) or 1-203-518-9783 (international).

To view the full press release, visit https://ibn.fm/T7ZZo

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations, including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in D-Wave Quantum Inc. QBTS | Leave a comment

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Its Board of Directors

  • CNS Pharmaceuticals recently appointed Amy Mahery, a biotech commercialization leader, to its Board of Directors
  • Ms. Mahery brings over 20 years’ experience, having worked with small and large companies, and has held diverse commercial leadership roles in the U.S. and globally
  • The company believes Ms. Mahery’s guidance, insight, and vast pharma industry network will indeed be invaluable as the company advances Berubicin, its flagship drug candidate, toward completion of its global potentially pivotal clinical trial and potential regulatory approval
  • The company recently completed the enrollment of patients in its potentially pivotal global clinical trial
  • Ms. Mahery believes Berubicin represents an opportunity to provide a solution for patients with GBM, the most aggressive type of brain cancer

With a fervent commitment to developing and commercializing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system, clinical-stage biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) continues to advance its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization. To boost these efforts, the company has enlisted an experienced, growing team. Recently, CNS Pharmaceuticals appointed Amy Mahery to its Board of Directors (https://ibn.fm/huSZ8).

A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and large companies in common and rare conditions, as well as across several therapeutic areas. She has held diverse commercial leadership roles in the U.S. and globally, spanning sales, marketing, and market access where she has been part of teams that commercialized and launched drugs in various therapeutic areas, from oncology and neurology to immunology.

In her current role as the Chief Commercial Officer of Roivant Sciences (NASDAQ: ROIV), a publicly traded biopharmaceutical company with a $9 billion market cap, Ms. Mahery is playing a vital role in facilitating Roivant’s transformation from a clinical development-focused company to an end-to-end biotech leader. She has worked to establish the company’s commercial operations and capabilities, efforts that have seen Roivant achieve profitable growth across its entire portfolio of over 10 affiliate companies called Vants. Ms. Mahery provides direct commercial leadership to the Vants during the start-up phase. Prior to taking up this role, she held multiple leadership roles at EMD Serono, Inc., a healthcare subsidiary of Merck KGaA.

“We are incredibly pleased to welcome Amy to the Board. She is a proven commercial leader with a wealth of knowledge and expertise amassed over the course of her 20+ years in the industry. As the company continues to advance Berubicin toward completion of its global potentially pivotal clinical trial and potential regulatory approval, her guidance, insight, and vast pharma industry network will truly be invaluable,” conveyed Faith L. Charles, Chair of the CNS Pharmaceuticals Board of Directors. “We remain committed to serving GBM patients in desperate need of a treatment, and look forward to leveraging Amy’s extensive experience and commercial leadership to assist in positioning the company for success.”

A strong supporter of innovation that brings value to patients, organizations, and society, Ms. Mahery lauded CNS Pharmaceuticals and its efforts to fill gaps in areas with high unmet medical needs, such as glioblastoma multiforme (“GBM”) treatment, saying, “I have been intrigued by the company’s pivotal trial design for Berubicin and was further compelled by the successful outcome from the recent interim analysis, the rapid pace of enrollment, and strong management team.”

Ms. Mahery believes Berubicin represents an opportunity to provide a solution for patients with GBM, the most aggressive type of brain cancer. Berubicin, an anthracycline, appears to cross the blood-brain barrier and kill cancer cells, as results from the completed Phase 1 human clinical trial show. The trial demonstrated positive responses that included one durable complete response.

CNS Pharmaceuticals is currently undertaking a potentially pivotal study of Berubicin for the treatment of GBM. The company completed in January the planned enrollment of 247 participants across 46 clinical trial sites in the U.S., Italy, France, Spain, and Switzerland (https://ibn.fm/dPOwp). The company remains hopeful in its efforts to address GBM and intends to take advantage of the extensive expertise of Ms. Mahery and other members of its capable team to drive success.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

Zoned Properties Inc. (ZDPY) Seeks to Bridge the Real Estate Shortage for the U.S. Cannabis Retail Operators

  • Many Landlords across the United States currently face several obstacles in leasing commercial properties to cannabis-focused tenants, on the basis of ongoing federal restrictions that impact real estate factors such as insurance, financing, and permitting
  • Zoned Properties has sought to bridge this supply gap, with a portfolio of investment properties seeking to address the needs of the regulated cannabis industry
  • The company has recently announced plans to refocus its investment portfolio towards direct-to-consumer retail properties, simultaneously revealing their intentions to market one of their cultivation-oriented sites for sale
  • Zoned Properties recently revealed that 3Q2023 revenues had risen by 17.2% YoY, whilst guiding for estimated full year rental revenues of $2.5 million over the course of 2024

In 2021, New York state officially legalized the usage of marijuana for recreational purposes; nevertheless, and nearly three years on from the landmark decision, cannabis supply for retail consumers remains painfully constrained. In April 2023, plans to build out a recreational cannabis dispensary in Harlem’s 125th street was thwarted by a lawsuit filed by a prominent Harlem business group, alleging that the planned dispensary would contribute to social issues in the neighborhood (https://ibn.fm/cB54T).

Despite cannabis being legal in 38 of 50 states for medical use and 24 states for recreational use, cannabis linked businesses are still faced with significant obstacles when looking to secure commercial properties for the cultivation or sale of marijuana-based products. With cannabis still illegal under federal law, commercial landlords seeking to rent out a mortgaged property face the risk of being called on a loan if a property is used for ‘illegal activity’; similarly, landlords open to leasing to cannabis tenants could face constraints in the form of city-specific zoning rules (https://ibn.fm/4XEBB). It is this unique conundrum which Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States, is seeking to address.

The United States’ cannabis industry is expected to benefit from a remarkable 13.93% CAGR from 2024 to 2028, resulting in an annual market size of $67.15 billion by the end of 2028. With a decade of national experience and a team of experts devoted to the emerging cannabis industry, Zoned Properties is seeking to capitalize on the industry’s burgeoning future by targeting commercial properties which have the potential to be acquired and rezoned or permitted for specific purposes, including the regulated and legalized cannabis industry. Separately and in addition to its core real estate development business, the company has sought to leverage upon their considerable commercial real estate expertise within their brokerage business in recent years; since 2021, Zoned Properties Brokerage has closed upwards of $80 million in commercial real estate deals nationally for clients.

Zoned Properties maintains a portfolio of six investment properties located across Arizona, Michigan and Illinois; with each of its leased properties occupied by commercial cannabis-linked businesses. The company currently enjoys a 100% occupancy rate with a weighted average lease term of over 10 years. In addition to maintaining four properties leased and repurposed as regulated cannabis retail dispensaries, the company leases two properties which are operated as regulated cannabis cultivation and processing facilities. Nonetheless, the company has recently sought to refocus its investment portfolio towards direct-to-consumer properties located in states boasting both, a regulated and legal domestic cannabis industry and robust underlying cannabis consumer demand; in doing so, Zoned Properties has announced that it now considers its cultivation sites as legacy properties, reserving the optionality to potentially sell or leverage these holdings to unlock equity to be deployed towards its core business.

Considering its reaffirmed commercial priorities, Zoned Properties recently revealed that the company has listed its cultivation property located in Chino Hills, Arizona for sale at a purchase price of $16 million. A valuable yet non-core asset within the company’s portfolio, the sale of the Chino Valley property could help further streamline Zoned Properties’ portfolio and help recalibrate its real estate offering towards more direct-to-consumer focused properties (https://ibn.fm/WWgDm).

“As part of our ongoing strategic review to enhance shareholder value, we are very pleased to announce our intention to sell our Chino Valley Property. The Chino Valley Property, which we now consider a non-core asset to our investment strategy, represents a significant capital reallocation opportunity for Zoned Properties. We expect that, if and when the Chino Valley Property is sold, the non-dilutive proceeds from the sale would be instrumental in supporting the company’s future real estate portfolio acquisition plans,” commented Bryan McLaren, Chief Executive Officer of Zoned Properties.

For more information, visit the company’s website at www.ZonedProperties.com.

NOTE TO INVESTORS: The latest news and updates relating to ZDPY are available in the company’s newsroom at https://ibn.fm/ZDPY

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Zoned Properties Inc. ZDPY | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Huge 2024 Milestone with FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

  • Lexaria, a global innovator in drug delivery platforms, recently received FDA clearance for its HYPER-H23-1 clinical study
  • John Docherty, President of Lexaria, has regarded this milestone as a demonstration of its patented DehydraTECH(TM) technology’s overall viability, particularly in the potential treatment of hypertension
  • With HYPER-H23-1, Lexaria looks to build on the success of its previous human clinical studies, whose results have been overwhelmingly positive
  • This marks a considerable milestone even as the company looks to double down on GLP-1 studies for the 2024 calendar year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that the U.S. Food and Drug Administration (“FDA”) has given it the requisite clearance to proceed with its planned U.S. Phase 1b hypertension clinical trial. This follows the company’s Investigational New Drug (“IND”) application earlier in the year.

The HYPER-H23-1 clinical trial, entitled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” will seek to explore the overall effectiveness of its patented DehydraTECH(TM)-processed CBD for the potential treatment of hypertension. The primary objective will be to evaluate the safety and tolerability in hypertensive patients, with secondary objectives including efficacy evaluation in reducing blood pressure and detailed pharmacokinetic testing (https://ibn.fm/ch6DA).

According to John Docherty, President of Lexaria, this clearance by the FDA demonstrates its technology’s overall potential, having met the FDA’s high level of regulatory scrutiny.

“This is a significant milestone achievement for Lexaria demonstrating, for the first time, that its DehydraTECH technology meets the FDA’s high level of regulatory scrutiny sufficient to formally commence U.S. registrational clinical testing towards possible future pharmaceutical commercialization,” noted Mr. Docherty.

Since 2018, Lexaria has conducted five human clinical studies for its DehydraTECH-CBD on 134 healthy, normal, and hypertensive volunteers. The results have been overwhelmingly positive, evidencing reductions in resting blood pressure over both acute and multi-week dosing regimens. The studies also produced zero serious adverse events, pointing to DehydraTECH’s potential to have pronounced clinical benefits relative to available anti-hypertensive therapeutics.

With HYPER-H23-1, Lexaria looks to build on the success of its previous studies, ultimately asserting the superiority of its technology, while also inching closer to tapping into the hypertension treatment market, which was valued at $31.76 billion in 2022, and is expected to reach $43.18 billion by 2030 (https://ibn.fm/Uror5).

“We look forward to commencing this important clinical trial and building upon the wealth of early-stage clinical data we have gathered and presented to the FDA to date demonstrating the safety, efficacy, and novel mechanistic performance of DehydraTECH-CBD in hypertensive patients,” noted Mr. Docherty.

This is a huge milestone for Lexaria and its team, especially following the plans to commence with its diabetes and weight loss animal study, coupled with doubling down on its GLP-1 clinical studies for the 2024 calendar year. All these steps reflect the company’s commitment to creating shareholder value and further developing its DehydraTECH technology, which has the potential to be a leader in its space.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Turbo Energy S.A. (NASDAQ: TURB) Providing ‘Best on the Market’ AI-Driven System

Turbo Energy (NASDAQ: TURB) is a designer, developer and manufacturer of photovoltaic energy generation, management and storage equipment. The company is seeking to harness artificial intelligence (“AI”) in the manufacture and development of its residential solutions, which allow households to capture and store solar energy. “The company’s ‘Sunbox Home’ system encompasses an all-in-one AI-powered energy storage solution, designed to assist households in managing their power consumption. Directly linked to a household’s solar panel generation unit, the Sunbox system allows users to choose between settings including ‘maximum consumption’ or ‘maximum savings,’ to conserve a portion of its energy reserves in the event of unexpected electricity blackouts or rather, sell excess power back onto the grid. The groundbreaking energy storage system additionally boasts the capacity to track weather forecasts, thus ensuring its batteries are fully charged in the event of a storm,” explains a recent article. “Turbo Energy’s artificial intelligence and optimization system is the best on the market,” said Turbo Energy CEO Mariano Soria. “[In addition to having] the capacity to offer the end consumer the best solution in economic savings, [our] software is the basis for the continued development of the company [as well as giving us] the ability to incorporate other elements in the future. We envision the ability to make use of it, not only for individuals but for groups such as energy communities or virtual power plants.”

To view the full article, visit https://ibn.fm/zWZdD

About Turbo Energy S.A.

Turbo Energy is a leading photovoltaic energy storage technology company based in Valencia, Spain. The company develops innovative solutions that allow end users to harness the full potential of solar energy and reduce their electricity costs. With a combination of artificial intelligence and advanced technology, Turbo Energy is paving the way toward a more sustainable and energy-efficient future. For more information, visit the company’s website at www.Turbo-E.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Turbo Energy S.A. TURB | Leave a comment

MissionIRNewsBreaks — SenesTech Inc. (NASDAQ: SNES) Is Expanding Global Reach with Innovative Products

SenesTech (NASDAQ: SNES) is dramatically improving pest management technicians’ toolboxes with its patent-pending Evolve(R) soft bait birth control product for rodents, which joins the liquid ContraPest(TM) product in providing non-lethal solutions to reducing rodent populations. “The patent-pending Evolve(TM) soft bait has a sausage-like appearance and poses little or no risk to human health or the environment – a significant advantage over poisons used to kill rats. SenesTech’s products are the first, and still the only, such rat contraceptives registered with the U.S. Environmental Protection Agency (‘EPA’) that target both male and female rats… The company recommends using its Birth Control for Rats(TM) products in tandem with other rodent control products, since rats that consume Evolve(TM) or ContraPest(R) will continue to live out their life cycles for months, just without adding new generations of pups. But SenesTech’s products can be used on their own if preferred,” a recent article reads. “The company’s reach is expanding globally – in addition to outlets across the United States, government entities in South Africa, the Maldives and, last month, the United Arab Emirates (‘UAE’) market have entered agreements with the company.”

To view the full article, visit https://ibn.fm/2FAud

About SenesTech Inc.

SenesTech is committed to improving the health of the world by humanely managing animal pest populations through fertility control. The company is an expert in fertility control to manage animal pest populations. It invented ContraPest(R), the only U.S. EPA-registered contraceptive for male and female rats, and Evolve(TM), an EPA-designated minimum risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. SenesTech strives for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable. For more information about the company, visit www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in SenesTech Inc. SNES | Leave a comment

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Publication of Peer-Reviewed Research for Investigational Drug CNM-Au8(R)

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced the publication of peer-reviewed research, titled “Protein Corona Composition of Gold Nanocrystals.” The publication appeared in the journal ACS Pharmacology & Translational Science and fully characterized the proteins from human blood plasma that form the protein corona of the gold nanocrystals of CNM-Au8(R), Clene’s investigational drug in development for the treatment of neurodegenerative diseases. “The protein corona of CNM-Au8 gold nanocrystals, tailored for brain delivery applications, exhibits a unique composition, notably enriched with critical apolipoproteins such as apolipoprotein E. This composition enhances the nanocrystals’ ability to traverse the blood-brain barrier. Simultaneously, the depletion of opsonin-based proteins in the corona extends their circulation time in the blood, as observed clinically. Our research underlines that these engineered gold nanocrystals, designed with specific structures and without surfactants, can form a distinct protein corona that facilitates access to brain tissue,” said Morteza Mahmoudi, associate professor in the Precision Health program and Department of Radiology at the Michigan State University College of Human Medicine.

To view the full press release, visit https://ibn.fm/KC87C

About Clene Inc.

Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Clene Inc. CLNN | Leave a comment

Turbo Energy (NASDAQ: TURB) Aligned with Rising EU and U.S. Renewable Energy Targets

  • EU raised 2030 binding renewable energy target to a minimum of 42.5%, aims to become climate-neutral by 2050
  • U.S. set goal of 100% clean energy by 2035
  • TURB aligned with renewable energy shift with Sunbox Home and Sunbox Industry
  • TURB’s all-in-one systems leverage AI to improve efficiency, prevent price shocks, and maximize cost savings
  • Turbo Community allows members with large PV installations to gain ownership of production, store extra power, and sell energy to market

The European Union recently raised its 2030 binding renewable target to a minimum of 42.5% with the aim of reaching 45% and becoming a climate-neutral continent by 2050 (https://ibn.fm/djHTQ). Across the Atlantic, the United States has set an even more ambitious goal of 100% clean energy by 2035 (https://ibn.fm/cqFtw).

Turbo Energy (NASDAQ: TURB), a photovoltaic energy company based in Spain, is strongly positioned to capitalize on the growing trend with its comprehensive range of patented energy storage and management solutions. By aligning its products and services with the evolving regulatory landscape, TURB aims to meet the growing needs of residential and commercial consumers while advancing the green transition.

TURB’s Sunbox Home is an AI-powered all-in-one energy storage system that manages consumption at each point on a home’s energy grid to maximize efficiency and cost savings (https://ibn.fm/Dh3X6). The battery optimizes energy management by strategically releasing stored energy during peak benefit periods while drawing back from the grid when electricity costs are low, ensuring efficient fulfillment. The system integrates electric vehicle charging capabilities with versatile modes, allowing consumers to charge at maximum speed, cost savings, or sustainably harnessing energy solely from the sun.

Sunbox’s protection modes safeguard consumers against price shocks through four customizable management modes. The Smart Mode leverages AI to strike a perfect balance between power consumption and savings on electricity bills. The system’s BackUp Mode allows users to designate a portion of the battery for blackout protection, ensuring system reliability. In Peak Shaving mode, users can reduce power bill costs by specifying which part of the storage delivers energy during overconsumption periods. Lastly, Sunbox’s Storm Protect mode activates an intelligent protection system that fully charges batteries in anticipation of upcoming storms based on weather forecast data.

TURB’s Sunbox Industry provides reliable energy generation and management for commercial businesses (https://ibn.fm/cG4eA). The system connects directly to rooftop panels and can be expanded with TURB’s Retrofit feature to leverage solar surpluses. With management modes like Sunbox Home, Sunbox Industry enables businesses to maximize power during outages, ensuring system efficiency and round-the-clock reliability. 

Turbo Energy goes beyond pioneering innovative energy systems that align with the global shift towards renewable energy. The company additionally empowers its clients to become part of the energy revolution through its Turbo Community (https://ibn.fm/8GxXV).

The Turbo Community enables users with large photovoltaic installations to gain ownership of their energy production by storing extra power for later use or selling it to the market as producers. Additionally, Turbo Energy provides opportunities to rent or finance solar energy systems, enabling users to access clean energy without significant upfront investment, maintenance issues, or installation concerns.

From its innovative products and services to its growing client network, Turbo Energy is dedicated to advancing the green transition. Led by a team with decades of technological, financial, and sales experience, the company is committed to a cleaner future amid the global push for renewable energy resources.

For more information, visit the company’s website at www.Turbo-e.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Turbo Energy S.A. TURB | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has appointed a new chief financial officer. The company announced that, effective immediately, Nelson Cabatuan, CPA, will serve in the position, which also entails being a member of Lexaria’s executive leadership team. Cabatuan brings more than 15 years of corporate finance and operations experience in the life sciences industry. Most recently, he served as senior vice president of finance and operations at Rain Oncology Inc., a late-stage precision oncology biotech company. In that position, he was pivotal in building and leading the company’s financial organization, resulting in significant growth while he was there. Cabatuan also held several positions at Rigel Pharmaceuticals Inc., including vice president finance. “Nelson’s deep financial leadership experience will be instrumental to the execution of Lexaria’s long-term growth strategy as we continue to maximize the potential use of our DehydraTECH platform for GLP-1 and other therapeutic applications with high unmet medical needs,” said Lexaria Bioscience CEO Chris Bunka in the press release. “On behalf of the entire Lexaria team, I’m thrilled to welcome Nelson as our CFO.”

To view the full press release, visit https://ibn.fm/qUMcs

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery formulation and processing platform technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Enrolls First Patients in Key Study Assessing Proprietary AIMIGo(TM) System

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has begun enrolling the first patients in its VALID-ECG pivotal study. According to the announcement, the first patients were enrolled at Atlanta Heart Specialists, a top cardiology physician practice in Atlanta, Georgia. HeartBeam anticipates the VALID-ECG study will form the basis of its planned FDA 510(k) submission. The study is designed to evaluate the performance of a 12-lead ECG synthesized from the credit-card-sized HeartBeam AIMIGo(TM) system compared to a standard hospital-based 12-lead ECG; the study will use both quantitative and qualitative methodologies for assessment of arrhythmias. The company anticipates enrolling some 198 patients in the program. “The initiation of the VALID-ECG study is a major milestone for the company and a reflection of our commitment to provide a strong foundation of clinical data as we strive to provide patients and physicians with the ability to accurately monitor cardiac disease outside of a medical facility,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “In addition, our product pipeline includes coupling AI with our data-rich 3D VECG technology, which will enable us to extract unique information and longitudinal insights to transform how cardiac care is monitored in the future.”

To view the full press release, visit https://ibn.fm/KDs3L

About HeartBeam Inc.

HeartBeam is a medical technology company dedicated to transforming cardiac care through the power of personalized insights. The company’s proprietary vectorelectrocardiography (“VECG”) technology collects 3D signals of the heart’s electrical activity and converts those signals into a 12-lead ECG. This platform technology is designed to be used on portable, patient-friendly devices such as a credit-card-sized monitor, watch or patch. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care, all outside of a medical facility, thus redefining how cardiac health is managed. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in HeartBeam Inc. BEAT | Leave a comment